IBA reported a 66% year-over-year increase in adjusted EBIT to €17.6 million for the first half of 2026, driven by strong demand for proton therapy systems. Revenue rose 6% to €323.7 million, while net profit swung to €9.3 million from a €2.6 million loss in the prior-year period.
The proton therapy segment generated €12.3 million in adjusted EBIT on €167.7 million in net sales, a sharp improvement from a €2.4 million loss in H1 2025. Equipment revenue climbed 12% to €101.7 million, supported by the delivery of four treatment rooms, while services revenue grew 3% to €66.0 million. The segment’s adjusted EBIT margin expanded to 7.3% from -1.4% a year earlier.
Order intake for proton therapy equipment surged nearly fivefold to €112 million, with five rooms sold compared to one in H1 2025. IBA now holds a 42% share of the global installed proton therapy rooms market, ahead of Varian at 21%, Hitachi at 19%, and Mevion at 9%. The company’s global footprint reached 93 sites, including 47 operating, 11 in installation, and 35 in production.
The Technologies division posted €127.0 million in net sales, up 10% year-over-year, but adjusted EBIT fell 37% to €8.2 million. Equipment order intake declined 48% to €28 million. The Dosimetry segment reported a 11% drop in net sales to €30.8 million, with adjusted EBIT turning negative at -1.7%.
PanTera, IBA’s radioisotope venture, generated €13.7 million in revenue and €6.7 million in EBITDA during H1 2026, supported by over 25 active customers and expanded partnerships, including a collaboration with TerraPower Isotopes to triple production capacity in Belgium. The company also reaffirmed full-year 2026 guidance for adjusted EBIT of at least €32 million and maintained its medium-term outlook targeting 5–7% revenue CAGR through 2028.
IBA’s shares traded near a 52-week high following the results, closing at €16.84, up 1.81%. Net debt increased to €81 million, while gross cash declined to €43.6 million.
